Xenetic Biosciences Inc.
XBIO
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3M
▲ +19.0% YoY
Net Income (TTM)
-$2M
▲ +32.3% YoY
Op. Margin
-81.01%
▲ +72.9pp YoY
ROIC
-34.24%
▲ +8.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▲ +18.8% YoY
Op. Cash Flow (TTM)
-$2M
▲ +18.8% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
5Y CAGR: +46.8%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with XBIO
Xenetic Biosciences (XBIO) in four numbers
Questions about Xenetic Biosciences
Is Xenetic Biosciences (XBIO) overvalued?
At $1.87, Xenetic Biosciences' price is 54% below the $4.05 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Xenetic Biosciences' fair value?
Intrinsiqq's calculator puts Xenetic Biosciences' fair value at $4.05 a share. It grows revenue per share 13.4% a year for 5 years, applies an exit P/S of 2.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $3.04. Every input can be changed on the Intrinsic Value tab.
Is Xenetic Biosciences a high-quality business?
Xenetic Biosciences scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 17.6%, and its weakest is return on capital at -34.2%. The Quality tab shows every check against its target.
Does Xenetic Biosciences (XBIO) pay a dividend?
No. Xenetic Biosciences (XBIO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in XBIO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing XBIO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.